DNAtrix Oncolytic Myxoma Virus Eliminates Treatment-Resistant Cancer

Thursday, May 11, 2017 Cancer News
Email Print This Page Comment
Font : A-A+

HOUSTON, May 11, 2017 /PRNewswire/ -- DNAtrix, a clinical stage biotechnology company developing oncolytic viruses for cancer,

today announced a podium presentation on the use of DNAtrix's oncolytic myxoma virus for treatment-resistant cancer at the upcoming 2017 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) in Washington,
DC
.

Grant McFadden, PhD, Director of the Biodesign Center for Immunotherapy, Vaccines and Virotherapy at Arizona State University, will present his pre-clinical results showing that ex vivo treatment of stem cells with myxoma virus prior to transplantation efficiently eliminates residual chemotherapy-resistant myeloma cells that remain in the transplant recipient.

Myxoma virus is an oncolytic poxvirus with the ability to selectively kill cancer cells without infecting or perturbing normal cells. More importantly, it can exploit T-cells and other white blood cells as virus "carriers," which can be systemically delivered to target and destroy tumors.

"This report by Dr. McFadden represents years of research to uncover the remarkable cancer-targeting properties of this virus," said Frank Tufaro, PhD, CEO of DNAtrix.  "It appears that myxoma virus could be especially effective in combination with T-cell-based therapies, such as CAR-T therapy and stem cell transplantation."

Details of the presentation are as follows:

Title: The Next Steps for Oncolytic Viral Therapies

Session: 305 - Designing the Next Generation of Viral Vectors Presenter: Grant McFadden, PhD Date: May 12, 2017, 9:10 - 9:45 am

About DNAtrix DNAtrix is a privately held, clinical stage, biotechnology company developing virus-driven immunotherapies for cancer. DNAtrix's lead product, DNX-2401, is a conditionally replicative oncolytic adenovirus being evaluated in clinical trials for recurrent glioblastoma, a brain cancer for which there is neither a cure nor adequate treatment. The company is backed by Morningside Ventures and Mercury Fund, and has been awarded a grant from the Cancer Prevention and Research Institute of Texas (CPRIT). For more information, please visit the company website at www.dnatrix.com.

Contact

DNAtrix Imran Alibhai, Ph.D. S.V.P. Business Development ialibhai@dnatrix.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/dnatrix-oncolytic-myxoma-virus-eliminates-treatment-resistant-cancer-300455939.html

SOURCE DNAtrix



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook